Award
National Cancer Institute 11324882
Study of tyrosine kinase inhibitors as preventive therapy in RUNX1-FPD
Recipient
University of Massachusetts Medical School Worcester, MA, USA
Award Amount
$485,790.00
Ceiling
$485,790.00
Awarded
April 29, 2026
Identifier
11324882
NIH-funded research project studying the preventive effects of tyrosine kinase inhibitors on blood cancer development in patients with RUNX1-FPD, a genetic blood disorder.
Description
This project aims to study cellular mechanisms driving cancer risk and evaluate whether imatinib, a drug used for chronic leukemia, can prevent or delay blood cancer development in individuals with a germline mutation in the gene RUNX1 causing Familial Platelet Disorder. The study investigates the role of RUNX1 mutations in DNA damage repair pathways, clonal hematopoiesis, and hematologic malignancies, and assesses the efficacy of tyrosine kinase inhibitors in preventing disease onset.